COMPARE · Data as of August 27, 2026

ADI vs SKHY

Verdict: Side-by-side breakdown using the Bull Rankings model. ADI scored 72.4, SKHY scored 72.0 — ADI leads.
Compare another set
Different reporting periods. ADI's fundamentals are as of August 2026, but SKHY's are as of March 2026 — a 4-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
ADI
Analog Devices, Inc.
Semiconductors · Quality-Growth
72.4
$371.80 · $180.2B
fundamentals as of
Score gap
0.4
ADI leads
SKHY
SK hynix Inc.
Semiconductors · Quality-Growth
72
$161.04 · $1.1T
fundamentals as of
  • CheapestSKHY9.8x
  • Fastest growthSKHY+46.8%
  • Strongest balance sheetSKHY0.08
  • Highest qualitySKHY92 / 100
THE BULL RANKINGS SCORECARD72.4/ 100 · BULL SCOREPEER MEDIANQUALITY73.4GROWTH92.3VALUE56.0
THE BULL RANKINGS SCORECARD72.0/ 100 · BULL SCOREPEER MEDIANQUALITY91.5GROWTH97.5VALUE79.9
ADISKHYQuality73.491.5Growth92.397.5Value56.079.9
cheap & fastrevenue growth →← cheaper (lower multiple)24%57%3.6x50xADISKHY

Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.

FCFADI$4.9bSKHY$29.5b
RevADI+33.6%SKHY+46.8%
D/EADI0.27SKHY0.08
P/EADI44.3xSKHY9.8x
PEGADI0.56SKHY0.31
ADI
stronger →← stronger
SKHY
73
Qualityreturns · margins · balance sheet
92
92
Growthrevenue & earnings expansion
98
56
Valuevaluation vs sector peers
80
SKHY is stronger on 3 of 3 pillars.
ADI
SKHY
$4.9bB
FCF
$29.5bA
+33.6%A
Rev
+46.8%A
0.27B
D/E
0.08B+
44.3xC+
P/E
9.8xA
0.56A-
PEG
0.31A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
ADI
SKHY
82% above
Price vs fair valuelower is cheaper
188% above
~31%/yr
Growth the price implies10-yr FCF · lower = less priced in
~46%/yr
-58%
1-yr DCF upside
-73%
-45%
5-yr DCF upside
-65%
-19%
10-yr DCF upside
-51%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
ADI
Why this score
  • Raising its dividend
SKHY
Why this score
  • Short track record
  • Foreign reporter (KRW)
ADIAnalog Devices, Inc.
Semiconductors · $371.80 · beta 1.21
Why now
Semiconductors · market cap $180.2b. 17% off the 52-week high of $445.91. Revenue growing +34% — in hypergrowth territory. PEG 0.56 — paying under fair value for the growth rate. 32 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $470.25 (implying +26% upside).
Moat
Net margin 30% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 119% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 44x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 13.0x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
SKHYSK hynix Inc.
Semiconductors · $161.04 · beta 2.40
Why now
Semiconductors · market cap $1.1T. 17% off the 52-week high of $194.80. Revenue growing +47% — in hypergrowth territory. PEG 0.31 — paying under fair value for the growth rate. 13 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $246.97 (implying +53% upside).
Moat
Net margin 86% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 93% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $1.1T market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk
Beta 2.40 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Semiconductor cyclicality — inventory corrections compress margins faster than analysts model. Monitor channel inventory and book-to-bill ratios as leading indicators.
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.

Where ADI and SKHY diverge

The two are effectively level on the headline score. The widest single difference is Value, where SKHY leads by 23.9 points.

Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.